Targeting T Cell Co-receptors for Cancer Therapy Review uri icon

Overview

MeSH Major

  • Antibodies, Blocking
  • Antibodies, Monoclonal
  • Immunotherapy
  • Neoplasms
  • T-Lymphocytes

abstract

  • Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells. At this time, the United States Food and Drug Administration has approved three checkpoint-blocking antibodies in three disease indications, and additional approvals are expected to broaden the clinical scope of immunotherapy. Herein, we review the clinical development of CTLA-4-, PD-1-, and PD-L1-blocking antibodies across tumor types and briefly discuss areas of active investigation of potential biomarkers.

publication date

  • May 17, 2016

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.immuni.2016.04.023

PubMed ID

  • 27192570

Additional Document Info

start page

  • 1069

end page

  • 78

volume

  • 44

number

  • 5